• Twitter
• Facebook
• Snapchat
• Pinterest
• LinkedIn
• Tumblr

---

Fundamental analysis: Aclaris Therapeutics, Inc. (ACRS)

Awarener score: 3.6

Conclusion

Note: All scores range from 1 (worst) to 10 (best). Conclusions are updated daily with closing stock prices and new reported quarterly financial statements.

Revenue score: 5.5

• Business has been growing at an extremely fast pace. It's been top tier when measured against peer companies.
• Aclaris Therapeutics, Inc. business varies wildly, ups and downs could be very frequent. It's very risky. It looks bottom tier against rivals.

Margins score: 1.8

• ACRS profit margins -on goods and services sold- are usually sufficient. They stand slightly worse than rival companies.
• Business profit on sales tends to be pauper. It's last-in-rank when measured against competitors.
• Profits on sales made -available to repay debt and purchase properties- are usually destitute. They remain a disappointment compared to peers.
• Earnings -before income taxes and interests on loans taken- tend to be pauper in relation to total revenues. They're still bottom tier against similar companies.
• Profits -before income taxes- are usually destitute considering total sales, and remain last-in-rank when measured against rivals.
• Total net profit tends to be pauper when confronted to sales. Company stands last-in-rank when measured against comparable firms.

Growth score: 2.3

• Aclaris Therapeutics, Inc. profit -on goods and services sold- has been growing at an extremely fast pace. It's been impressive in relation to competitors.
• In recent years, the firm hasn't always been able to profit from operations, which has been bottom tier against comparable firms.
• In past years, the company couldn't always turn a profit -available to repay debt and purchase properties-, which compares last-in-rank when measured against peer enterprises.
• In the previous years, the firm couldn't always make a profit -before income taxes and interests on loans taken-. It turns to be a disappointment compared to similar stocks.
• In past years, at least once the company lost money -before income taxes-. It was bottom tier against rivals.
• In the previous years, the firm had at least a total net loss, and last-in-rank when measured against peer companies.
• The company lost money at least once in the past years. It's been a disappointment compared to industry peers.

Miscellaneous score: 2.3

• ACRS had still to pay income taxes, even though in recent past years mostly lost money. It's been bottom tier against peers.
• Research and development expenses consume a very large portion of revenues. It's last-in-rank when measured against competitors.
• The company grows very little in relation to research and development efforts. It stands in a very weak position compared to rival companies.

Profitability score: 1.0

• Aclaris Therapeutics, Inc. usually gets pauper returns on the resources it controls. It proves substantially worse when measured against peer firms.
• The company normally gets extremely poor proceeds -on the resources directly invested in the business-. They remain in a very weak position compared to similar companies.
• There's usually bottom profitability -in relation to owned resources-. It ranks weak when measured against competitors.
• In the past, got pauper returns -on the tangible resources it controls-. This metric is usually related to the industry in which operates and combines profitability versus reinvestment needs. It's substantially worse when measured against comparable enterprises.

Usage of Funds score: 1.2

• ACRS on average doesn't generate genuine funds, so to buy or replace property, plants and equipment must either burn existing cash or increase debt. It stands substantially worse when measured against rival firms.
• The company is usually not replacing property, plant, and equipment that gets old, instead using funds in something else. It can't keep forever, which is last-in-rank when measured against industry peers.
• In the past twelve months the stock paid no dividends. It came bottom tier against competitors.
• The company pays no dividend, so measuring its growth is meaningless. The company has behaved in an conservative way compared to similar firms.
• As no dividends are paid, it is useless trying to estimate their sustainability in time. Sustainability looks not applicable in regard to comparable companies.
• The company has greatly enlarged the pool of investors in previous years, resulting in more mouths feeding on the pie of profits. It remains a disappointment compared to peer enterprises.
• Repurchase effectiveness metric is very complex. Run again in analytical mode if you're interested in a technical explanation. It stands in a very weak position compared to rivals.
• We do not have sufficient data to comment on buybacks and their sustainability. It still looks dubious against competitors.

Balance Sheet score: 6.5

• Aclaris Therapeutics, Inc. has not disclosed intangibles assets, so we could not reach a meaningful conclusion on this metric. It happens to be a not known variable when measured with peer companies.
• Current ratio remains a mystery, as there was not sufficient Balance Sheet information. It turns to be unidentifiable against similar firms.
• The relation between debt and assets is unknown to us. It remains undisclosed against rival firms.
• We have not enough inputs to assess how quickly assets can be turned into cash and equivalents. It looks we are not able to reach a conclusion in relation to rivals.
• Quick ratio is unavailable at this moment, due to lacking data. It's a pity we cannot compare it with peer firms.
• A conclusion on cash ratio could not be reached, as we lack inputs, which is unfortunate when trying to measure against similar enterprises.
• Usually, sales are mostly on cash. It still ranks top tier when measured against peers.
• Normally has no inventories. It comes up as impressive in relation to competitors.
• On average, it takes less than one month from the purchase to charging customers. It happens to be top-notch against peers.
• Pays suppliers mostly in cash. It ranks last-in-rank when measured against industry peers.
• The company pays its suppliers almost when charging its customers, so there's very little money invested in working capital. It's in good shape compared to similar companies.
• Has usually been losing money on the business, so net interest expenses must be paid by increasing borrowings, which is unsustainable in the long run. The situation is very risky for both creditors and shareholders, profitability must increase. It stands bottom tier against rival firms.
• There is insufficient data to conclude on the relationship of EBITDA and debt for this company. It ranks unknown against comparable enterprises.
• Fixed assets turnover remains undisclosed. It looks we cannot relate it to similar firms.
• We did not reach a conclusion regarding total assets turnover, as not enough data is currently available. It's still unable to match with peer companies.

Valuation score: 2.3

• Aclaris Therapeutics, Inc. reported losses, so valuating it in relation to earnings is meaningless. It happens to be last-in-rank when measured against competitors.
• We have not enough data to conclude on the relationship of price versus tangible book value for this company. It remains therefore unknown compared to peers.
• In the past twelve months, the company consumed funds. Either it reinvested in the business or genuine fund generation might be challenging, which stands slightly worse than similar companies.
• The company usually consumes more funds than can genuinely generate. Business needs are meet by borrowing money or consuming preexistent cash, which can only keep up until a certain limit. Unless the company is driving business growth, genuine profitability may be brought into question. It's still below average when measured against industry firms.
• In the past twelve months, the company has greatly enlarged the pool of investors by issuing new shares. Future profits need to be high enough to justify the measure, as the pie of earnings will now be split among plenty more stockholders. It came up a disappointment compared to peer ventures.
• The company has neither net debt nor net cash. It may borrow extra money if it wishes so, or start cumulating cash for future uses. It looks somewhat better than similar enterprises.
• Considering the past twelve months, traditional Price-to-Earnings relation has been negative, as the company lost money. It ranks last-in-rank when measured against peer companies.
• Comparing the current stock price with the past twelve-months revenues gives a huge relationship. The stock price might rely more on expectations and resources controlled than on anything else. It looks a disappointment compared to rival firms.
• We have not enough information on the relation between current stock price and accounting book value. The company remains a mystery against peer firms.
• In the past twelve months, the operating business lost significant money. It happens to be almost average when measured against industry peers.
• In an alternate metric of bang for the buck, the company has usually shown a very low earnings power ability when measured against the current stock price and financial position. Profitability is in dispute. It's still close to average when compared to peer companies.

Total score: 2.9

---

Awarener score: 3.6

Conclusion

Support us!

We are an independent project. No ads, no suscription, no registration required.

• Donate!